Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) have received an average rating of “Moderate Buy” from the twenty-one analysts that are covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The average 12-month target […]
StockNews.com upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) from a buy rating to a strong-buy rating in a research report sent to investors on Tuesday. Other research analysts have also issued reports about the company. Morgan Stanley reissued an overweight rating and set a $130.00 price target on shares of Neurocrine Biosciences in […]
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by StockNews com theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
StockNews.com cut shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) from a strong-buy rating to a buy rating in a research report sent to investors on Monday morning. A number of other equities research analysts have also recently issued reports on NBIX. Robert W. Baird boosted their target price on shares of Neurocrine Biosciences from […]
Rhenman & Partners Asset Management AB decreased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 17.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 70,000 shares of the company’s stock after selling 15,000 shares during the quarter. Rhenman & Partners […]